P
ONC

&Partners’s BeOne Medicines Ltd ONC Stock Holding History

&Partners’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$859K Buy
2,887
+284
+11% +$91.9K ﹤0.01% 1381
2025
Q4 		$791K Buy
2,603
+840
+48% +$275K ﹤0.01% 1351
2025
Q3 		$601K Buy
1,763
+55
+3% +$16.7K ﹤0.01% 1348
2025
Q2 		$413K Buy
1,708
+211
+14% +$51.7K ﹤0.01% 1446
2025
Q1 		$400K Sell
1,497
-35
-2% -$8.18K ﹤0.01% 1246
2024
Q4 		$277K Buy
1,532
+499
+48% +$102K ﹤0.01% 1381
2024
Q3 		$232K Buy
+1,033
New +$186K ﹤0.01% 1234

Other funds holding ONC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

&Partners's ONC Position: Q1 2026 in Review

&Partners increased its BeOne Medicines Ltd (ONC) stake by 11% in Q1 2026, buying an estimated $91.9K and bringing the position to 2,887 shares worth $859K. The position accounts for ﹤0.01% of the portfolio, ranked #1381.

&Partners first reported a position in ONC in Q3 2024 and has held it in 7 quarters since. 281 funds tracked by Wall St. Rank hold ONC as of Q1 2026.

  • &Partners held 2,887 shares of BeOne Medicines Ltd worth $859K as of Q1 2026.
  • &Partners bought 284 BeOne Medicines Ltd shares in Q1 2026, an estimated $91.9K.
  • BeOne Medicines Ltd made up ﹤0.01% of &Partners's portfolio in Q1 2026, its #1381 holding.
  • &Partners first reported a position in BeOne Medicines Ltd in Q3 2024 and has held it in 7 quarters since.
  • 281 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.